An inhalable version of the drug oxytocin could slash the number of women dying in childbirth, researchers say.
About 300,000 women die from childbirth a year, primarily from postpartum haemorrhaging (PPH) and in developing countries such as Afghanistan.
Oxytocin is currently an injectable drug administered to women experiencing signs of PPH in pregnancy, and works by stimulating the uterine muscles.
Associate professor Michelle McIntosh, from the Monash Institute of Pharmaceutical Sciences, has developed the first human trial to deliver the drug in an inhaled form.
“At the end of childbirth the uterus is just tired and it sort of stops contracting, so just an injection or an extra dose of oxytocin, it just prompts that contractility to start again,” Dr McIntosh said.
However in its current form it needs to be refrigerated and a skilled medical professional to properly administer it.
“And that’s not really suitable for a lot of remote or rural locations, particularly in low-resource settings,” Dr McIntosh said.
“Women are going to give birth late at night, there’s no lights, there’s no electricity, there’s nobody there to help.”
She said the drug needed to be able to be administered in a simple way, so that any healthcare worker or community-based healthcare worker could assist a woman immediately after childbirth.